Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab +/- Azacitidine in MDS
NCT02508870Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atezolizumab in myelodysplastic syndrome (MDS) (6 cohorts), sponsored by Roche. Primary endpoints: Percentage of Participants with Dose Limiting Toxicities, Recommended Phase 2 Dose and 1 more. Started Sep 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02508870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508870.